Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for BMS-986463](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic: Canada, United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Non-Small-Cell Lung Cancer|Ovarian Cancer|Serous Cystadenocarcinoma|Uterine Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CA231-0000 | P1 |
Recruiting |
Uterine Cancer|Serous Cystadenocarcinoma|Ovarian Cancer|Non-Small-Cell Lung Cancer |
2028-12-19 |